Unsachgemäße Systemtherapie bei schwerer atopischer Dermatitis – fatale Langzeitschäden
Related Research units
Abstract
The therapeutic options for treatment of severe cases of atopic dermatitis have been limited until recently, but fundamentally improved with the approval of the first biological dupilumab at the end of 2017. With the biological tralokinumab and the Janus kinase inhibitors baricitinib and upadacitinib, further new systemic drugs have recently been approved. Nevertheless, there are cases in which modern treatment options are not taken into account, as shown by a 28-year-old patient with serious side effects from long-term treatment with systemic glucocorticoids. In addition to the extensive clarification of the consequential damage, guideline-based therapy with dupilumab was initiated as well as interdisciplinary cooperation with endocrinologists, ophthalmologists, osteologists and nutritionists.
Bibliographical data
Translated title of the contribution | Inappropriate systemic therapy in severe atopic dermatitis-severe long-term damage |
---|---|
Original language | German |
ISSN | 0017-8470 |
DOIs | |
Publication status | Published - 08.2022 |
Comment Deanary
© 2021. The Author(s).
PubMed | 34905073 |
---|